Idiotype-pulsed antigen presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival

Vaccines are attractive as consolidation therapy after autologous stem cell transplantation (ASCT) for multiple myeloma (MM). We report the results of a phase II trial of the immunotherapeutic, APC8020 (Mylovenge™), given after ASCT for MM. We compared the results with that of other patients with MM...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Lacy, Martha Q., Mandrekar, Sumithra, Dispenzieri, Angela, Hayman, Suzanne, Kumar, Shaji, Buadi, Francis, Dingli, David, Litzow, Mark, Wettstein, Peter, Padley, Douglas, Kabat, Brian, Gastineau, Dennis, Rajkumar, S. Vincent, Gertz, Morie A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2009
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2908015/
https://ncbi.nlm.nih.gov/pubmed/19899131
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.21560
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi